

# Alibaba (BABA US)

## Offering of exchangeable bonds to support international business development

Alibaba Group (Alibaba) announced the proposed offering of exchangeable bonds by reference to the ordinary share of Alibaba Health (Ali Health) on 3 Jul. Alibaba proposed to offer HK\$12bn aggregated principal amount of zero coupon bonds due 2032, and intends to use the net proceeds for general corporate purposes, including investment to support the development of cloud infrastructure and international commerce business. Alibaba can elect to satisfy its exchange obligation to holders of the bonds by delivering AH shares, cash, or a combination of cash and AH shares of Ali Health. Alibaba currently holds c. 64% of the equity interest of Ali Health, and the initial exchange property referenced by the bond will represent up to c. 12% of the total shares of Ali Health assuming the bonds are exchanged in full for AH shares. Ali Health will remain a consolidated subsidiary of Alibaba upon bond issuance and following any future exchange of the bonds into AH shares. We expect the issuance of bonds to help Alibaba enhance overseas capital for international expansion in the near term, and to help Ali Health increase free float upon future exchange. Maintain BUY on Alibaba with an unchanged SOTP-based TP of US\$155.5.

- **Pricing details of the bonds.** The initial exchange ratio of the bonds will be c.160,513.6 AH shares per HK\$1mn principal amount of bonds, which is equivalent to an initial exchange price of HK\$6.23 per AH share of Ali Health. This represents a premium of 48% over the market close price per share of Ali Health on 3 July. Bondholders may exchange all or any portion of the bonds at their option at any time on or after the 41st day following the issue date of the bonds, and including, the close of business on the fifth scheduled trading day immediately preceding the maturity date of the bonds.
- **Issuance of the bonds should enhance capital for international expansion.** International expansion is one of Alibaba's important long-term development strategies, and we believe the issuance of the exchangeable bonds should help facilitate sufficient offshore funds to support overseas business development of both cloud and digital commerce business of Alibaba. As of 31 Mar 2025, Alibaba's cash and cash equivalent, short-term investment, and other treasury investment totalled RMB597.1bn, and we are anticipating an adjusted EBITA loss of RMB3.5bn for Alibaba International Digital Commerce Group in FY26E (March year-end). We expect Ali Health to remain a flagship healthcare platform and a consolidated subsidiary of Alibaba upon bond issuance and following any future exchange of the bonds into AH shares, and will continue to collaborate closely with Alibaba ecosystem to drive "AI + Healthcare" industry transformation.

### Earnings Summary

(YE 31 Mar)	FY24A	FY25A	FY26E	FY27E	FY28E
Revenue (RMB mn)	941,168	996,347	1,041,023	1,118,003	1,183,412
YoY growth (%)	8.3	5.9	4.5	7.4	5.9
Net profit (RMB mn)	79,741.0	129,470.0	146,001.0	165,295.6	185,593.8
Adjusted net profit (RMB mn)	158,359.0	157,940.0	166,821.5	186,537.6	206,895.2
YoY growth (%)	10.0	(0.3)	5.6	11.8	10.9
EPS (Adjusted) (RMB)	62.77	67.24	73.22	84.40	93.62
P/E (x)	25.1	14.4	12.4	10.6	9.4
ROE (%)	8.0	12.8	11.9	10.8	10.8

Source: Company data, Bloomberg, CMBIGM estimates

**BUY (Maintain)**

**Target Price** US\$155.50  
**Up/Downside** 40.5%  
**Current Price** US\$110.71

### China Internet

**Saiyi HE, CFA**  
 (852) 3916 1739  
 hesaiyi@cmbi.com.hk

**Ye TAO, CFA**  
 franktao@cmbi.com.hk

**Wentao LU, CFA**  
 luwentao@cmbi.com.hk

**Joanna Ma**  
 (852) 3761 8838  
 joannama@cmbi.com.hk

### Stock Data

Mkt Cap (US\$ mn)	259,316.9
Avg 3 mths t/o (US\$ mn)	797.7
52w High/Low (US\$)	147.57/73.50
Total Issued Shares (mn)	2342.3

Source: FactSet

### Shareholding Structure

Blackrock	5.0%
Softbank	4.9%


Source: HKEx

### Share Performance

	Absolute	Relative
1-mth	-3.7%	-8.4%
3-mth	-14.4%	-30.5%
6-mth	29.4%	24.5%

Source: FactSet

### 12-mth Price Performance



Source: FactSet

## Financial Summary

INCOME STATEMENT	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Mar (RMB mn)						
Revenue	868,687	941,168	996,347	1,041,023	1,118,003	1,183,412
Cost of goods sold	(549,695)	(586,323)	(598,285)	(619,409)	(661,858)	(700,580)
Gross profit	318,992	354,845	398,062	421,614	456,145	482,832
Operating expenses	(218,641)	(241,495)	(257,157)	(246,057)	(253,072)	(248,943)
SG&A expense	(145,679)	(157,126)	(188,260)	(182,179)	(186,706)	(181,062)
R&D expense	(56,744)	(52,256)	(57,151)	(57,632)	(59,657)	(60,781)
Others	(16,218)	(32,113)	(11,746)	(6,246)	(6,708)	(7,100)
Operating profit	100,351	113,350	140,905	175,558	203,073	233,889
Interest income	(11,071)	(9,964)	20,759	4,164	4,248	4,260
Interest expense	(5,918)	(7,947)	(9,596)	(10,026)	(10,209)	(10,806)
Other income/expense	5,823	6,157	3,387	5,726	5,590	5,680
Pre-tax profit	89,185	101,596	155,455	175,421	202,703	233,024
Income tax	(15,549)	(22,529)	(35,445)	(38,943)	(47,635)	(58,256)
Others	(8,063)	(7,735)	5,966	5,205	5,590	5,917
After tax profit	65,573	71,332	125,976	141,683	160,658	180,685
Minority interest	7,210	8,677	4,133	4,318	4,638	4,909
Others	(274)	(268)	(639)	0	0	0
Net profit	72,509	79,741	129,470	146,001	165,296	185,594
Adjusted net profit	143,991	158,359	157,940	166,821	186,538	206,895

BALANCE SHEET	2023A	2024A	2025A	2026E	2027E	2028E
YE 31 Mar (RMB mn)						
Current assets	697,966	752,864	674,049	889,672	976,467	1,078,815
Cash & equivalents	193,086	248,125	145,487	407,132	483,498	577,283
Restricted cash	36,424	38,299	43,781	43,781	43,781	43,781
Prepayment	137,072	143,536	202,175	156,154	166,582	175,145
Financial assets at FVTPL	331,384	322,904	282,606	282,606	282,606	282,606
Non-current assets	1,055,078	1,011,965	1,130,178	1,351,179	1,480,466	1,610,425
PP&E	176,031	185,161	203,348	432,754	547,184	662,893
Investment in JVs & assos	207,380	203,131	210,169	222,412	235,040	247,995
Intangibles	46,913	26,950	20,911	23,314	23,314	23,314
Goodwill	268,091	259,679	255,501	255,501	255,501	255,501
Financial assets at FVTPL	245,737	220,942	356,818	356,818	356,818	356,818
Other non-current assets	110,926	116,102	83,431	60,379	62,608	63,904
Total assets	1,753,044	1,764,829	1,804,227	2,240,851	2,456,933	2,689,241
Current liabilities	385,351	421,507	435,346	412,605	445,941	476,472
Short-term borrowings	7,466	12,749	22,562	23,359	24,959	26,420
Tax payable	12,543	9,068	11,638	31,934	37,632	44,274
Other current liabilities	89,392	101,807	68,609	71,031	75,899	80,340
Accrued expenses	275,950	297,883	332,537	286,281	307,451	325,438
Non-current liabilities	244,772	230,723	278,775	282,534	290,088	296,979
Long-term borrowings	52,023	55,686	49,909	49,909	49,909	49,909
Deferred income	3,560	4,069	4,536	4,696	5,018	5,312
Other non-current liabilities	189,189	170,968	224,330	227,929	235,161	241,758
Total liabilities	630,123	652,230	714,121	695,139	736,029	773,451
Share capital	1	1	1	1	1	1
Capital surplus	416,880	397,999	381,379	481,775	496,309	510,510
Retained earnings	599,028	597,897	645,478	955,147	1,120,443	1,306,036
Other reserves	(16,394)	1,375	(5,287)	2,511	2,511	2,511
Total shareholders equity	999,515	997,272	1,021,571	1,439,434	1,619,264	1,819,058
Minority interest	123,406	115,327	68,535	106,278	101,640	96,731
Total equity and liabilities	1,753,044	1,764,829	1,804,227	2,240,851	2,456,933	2,689,241

CASH FLOW	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Mar (RMB mn)</b>						
<b>Operating</b>						
Profit before taxation	89,185	101,596	155,455	175,421	202,703	233,024
Depreciation & amortization	46,938	44,504	14,886	14,796	15,258	15,650
Tax paid	(15,549)	(22,529)	(35,445)	(38,943)	(47,635)	(58,256)
Change in working capital	13,482	(13,749)	(68,323)	105,948	22,837	22,642
Others	65,696	72,771	96,936	16,463	18,328	17,662
<b>Net cash from operations</b>	<b>199,752</b>	<b>182,593</b>	<b>163,509</b>	<b>273,684</b>	<b>211,491</b>	<b>230,722</b>
<b>Investing</b>						
Capital expenditure	(34,330)	(32,087)	(92,660)	(119,718)	(122,980)	(124,258)
Acquisition of subsidiaries/ investments	(22)	(842)	4,178	(6,000)	(6,708)	(7,100)
Net proceeds from disposal of short-term investments	(61,086)	71,426	(34,129)	0	0	0
Others	(40,068)	(60,321)	(62,804)	(7,038)	(7,038)	(7,038)
<b>Net cash from investing</b>	<b>(135,506)</b>	<b>(21,824)</b>	<b>(185,415)</b>	<b>(132,756)</b>	<b>(136,726)</b>	<b>(138,396)</b>
<b>Financing</b>						
Net borrowings	0	0	0	0	0	0
Proceeds from share issues	11	843	0	0	0	0
Share repurchases	(74,746)	(88,745)	0	0	0	0
Others	9,116	(20,342)	(76)	797	1,601	1,460
<b>Net cash from financing</b>	<b>(65,619)</b>	<b>(108,244)</b>	<b>(76)</b>	<b>797</b>	<b>1,601</b>	<b>1,460</b>
<b>Net change in cash</b>						
Cash at the beginning of the year	227,353	229,510	286,424	265,407	407,132	483,498
Exchange difference	3,530	4,389	965	0	0	0
<b>Cash at the end of the year</b>	<b>229,510</b>	<b>286,424</b>	<b>265,407</b>	<b>407,132</b>	<b>483,498</b>	<b>577,283</b>
GROWTH	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Mar</b>						
Revenue	1.8%	8.3%	5.9%	4.5%	7.4%	5.9%
Gross profit	1.7%	11.2%	12.2%	5.9%	8.2%	5.9%
Operating profit	44.1%	13.0%	24.3%	24.6%	15.7%	15.2%
Net profit	17.0%	10.0%	62.4%	12.8%	13.2%	12.3%
Adj. net profit	0.3%	10.0%	(0.3%)	5.6%	11.8%	10.9%
PROFITABILITY	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Mar</b>						
Gross profit margin	36.7%	37.7%	40.0%	40.5%	40.8%	40.8%
Operating margin	11.6%	12.0%	14.1%	16.9%	18.2%	19.8%
Adj. net profit margin	16.6%	16.8%	15.9%	16.0%	16.7%	17.5%
Return on equity (ROE)	7.4%	8.0%	12.8%	11.9%	10.8%	10.8%
GEARING/LIQUIDITY/ACTIVITIES	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Mar</b>						
Net debt to equity (x)	(0.4)	(0.4)	(0.2)	(0.3)	(0.3)	(0.4)
Current ratio (x)	1.8	1.8	1.5	2.2	2.2	2.3
VALUATION	2023A	2024A	2025A	2026E	2027E	2028E
<b>YE 31 Mar</b>						
P/E	28.7	25.1	14.4	12.4	10.6	9.4
P/E (diluted)	28.9	25.3	14.8	12.7	10.9	9.7
P/B	2.1	2.0	1.9	1.3	1.1	1.0
P/CFPS	12.6	13.4	27.0	12.1	20.4	16.9

Source: Company data, CMBIGM estimates. Note: The calculation of net cash includes financial assets.

# Disclosures & Disclaimers

## Analyst Certification

The research analyst who is primary responsible for the content of this research report, in whole or in part, certifies that with respect to the securities or issuer that the analyst covered in this report: (1) all of the views expressed accurately reflect his or her personal views about the subject securities or issuer; and (2) no part of his or her compensation was, is, or will be, directly or indirectly, related to the specific views expressed by that analyst in this report. Besides, the analyst confirms that neither the analyst nor his/her associates (as defined in the code of conduct issued by The Hong Kong Securities and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue of this report; (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report; (3) serve as an officer of any of the Hong Kong listed companies covered in this report; and (4) have any financial interests in the Hong Kong listed companies covered in this report.

## CMBIGM Ratings

**BUY** : Stock with potential return of over 15% over next 12 months  
**HOLD** : Stock with potential return of +15% to -10% over next 12 months  
**SELL** : Stock with potential loss of over 10% over next 12 months  
**NOT RATED** : Stock is not rated by CMBIGM

**OUTPERFORM** : Industry expected to outperform the relevant broad market benchmark over next 12 months  
**MARKET-PERFORM** : Industry expected to perform in-line with the relevant broad market benchmark over next 12 months  
**UNDERPERFORM** : Industry expected to underperform the relevant broad market benchmark over next 12 months

## CMB International Global Markets Limited

**Address:** 45/F, Champion Tower, 3 Garden Road, Hong Kong, Tel: (852) 3900 0888 Fax: (852) 3900 0800

**CMB International Global Markets Limited ("CMBIGM") is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned subsidiary of China Merchants Bank)**

## Important Disclosures

There are risks involved in transacting in any securities. The information contained in this report may not be suitable for the purposes of all investors. CMBIGM does not provide individually tailored investment advice. This report has been prepared without regard to the individual investment objectives, financial position or special requirements. Past performance has no indication of future performance, and actual events may differ materially from that which is contained in the report. The value of, and returns from, any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the performance of underlying assets or other variable market factors. CMBIGM recommends that investors should independently evaluate particular investments and strategies, and encourages investors to consult with a professional financial advisor in order to make their own investment decisions.

This report or any information contained herein, have been prepared by the CMBIGM, solely for the purpose of supplying information to the clients of CMBIGM or its affiliate(s) to whom it is distributed. This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in securities or enter into any transaction. Neither CMBIGM nor any of its affiliates, shareholders, agents, consultants, directors, officers or employees shall be liable for any loss, damage or expense whatsoever, whether direct or consequential, incurred in relying on the information contained in this report. Anyone making use of the information contained in this report does so entirely at their own risk.

The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable. CMBIGM has exerted every effort in its capacity to ensure, but not to guarantee, their accuracy, completeness, timeliness or correctness. CMBIGM provides the information, advices and forecasts on an "AS IS" basis. The information and contents are subject to change without notice. CMBIGM may issue other publications having information and/ or conclusions different from this report. These publications reflect different assumption, point-of-view and analytical methods when compiling. CMBIGM may make investment decisions or take proprietary positions that are inconsistent with the recommendations or views in this report.

CMBIGM may have a position, make markets or act as principal or engage in transactions in securities of companies referred to in this report for itself and/or on behalf of its clients from time to time. Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with the companies in this report. As a result, recipients should be aware that CMBIGM may have a conflict of interest that could affect the objectivity of this report and CMBIGM will not assume any responsibility in respect thereof. This report is for the use of intended recipients only and this publication, may not be reproduced, reprinted, sold, redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM.

Additional information on recommended securities is available upon request.

### For recipients of this document in the United Kingdom

This report has been provided only to persons (I) falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended from time to time) ("The Order") or (II) are persons falling within Article 49(2) (a) to (d) ("High Net Worth Companies, Unincorporated Associations, etc.") of the Order, and may not be provided to any other person without the prior written consent of CMBIGM.

### For recipients of this document in the United States

CMBIGM is not a registered broker-dealer in the United States. As a result, CMBIGM is not subject to U.S. rules regarding the preparation of research reports and the independence of research analysts. The research analyst who is primary responsible for the content of this research report is not registered or qualified as a research analyst with the Financial Industry Regulatory Authority ("FINRA"). The analyst is not subject to applicable restrictions under FINRA Rules intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report. This report is intended for distribution in the United States solely to "major US institutional investors", as defined in Rule 15a-6 under the US, Securities Exchange Act of 1934, as amended, and may not be furnished to any other person in the United States. Each major US institutional investor that receives a copy of this report by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person. Any U.S. recipient of this report wishing to effect any transaction to buy or sell securities based on the information provided in this report should do so only through a U.S.-registered broker-dealer.

### For recipients of this document in Singapore

This report is distributed in Singapore by CMBI (Singapore) Pte. Limited (CMBISG) (Company Regn. No. 201731928D), an Exempt Financial Adviser as defined in the Financial Advisers Act (Cap. 110) of Singapore and regulated by the Monetary Authority of Singapore. CMBISG may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, as defined in the Securities and Futures Act (Cap. 289) of Singapore, CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact CMBISG at +65 6350 4400 for matters arising from, or in connection with the report.